Historical elv News Stories
Elevance (ELV) Faces 2026 Downturn, Stock Repriced
Elevance Health (ELV) has cut its 2026 outlook, forecasting lower revenue, reduced EPS guidance and significant Medicaid membership losses. Coupled with a near-zero Medicare Advantage rate proposal and sector-wide sell-off, these developments triggered sharp stock repricing and elevated investor scrutiny.
Elevance (ELV) Faces Rising Medicaid Cost Pressure
Elevance Health (ELV) posted a mixed quarter—EPS beat but revenue slightly missed—while management warned of elevated Medicaid and ACA medical costs that threaten near-term margin improvement. The stock sold off following cost guidance, an institutional trimming was reported, and a modest dividend raise underscores cash resilience. Key watchpoints: medical-cost trends, updated guidance, and peer comparisons.